{"entity":{"id":"angpt1","kind":"target","name":"ANGPT1","aka":["angiopoietin 1","Angiopoietin-1","KIAA0003","Ang1","AGPT-1"],"tldr":"ANGPT1 (Angiopoietin-1) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","summary":"Binds and activates TEK/TIE2 receptor by inducing its dimerisation and tyrosine phosphorylation. Plays an important role in the regulation of angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganisation of the actin cytoskeleton, but also maintenance of vascular quiescence. Required for normal angiogenesis and heart development during embryogenesis.\n\nOpen Targets scores its association with cancer at 0.51 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.44, clinical 0.68).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:484","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:484"},{"label":"UniProt Q15389","url":"https://www.uniprot.org/uniprotkb/Q15389/entry"},{"label":"NCBI Gene 284","url":"https://www.ncbi.nlm.nih.gov/gene/284"},{"label":"Ensembl ENSG00000154188","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000154188"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.68. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"ANGPT1","role":["drug-target"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:484","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:484","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q15389","url":"https://www.uniprot.org/uniprotkb/Q15389/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000154188","url":"https://platform.opentargets.org/target/ENSG00000154188/associations","note":"association with cancer (MONDO_0004992) 0.51;  (GraphQL API, CC0)"}],"distribution":"not-established","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ANGPT1: RNA tissue enhanced (seminal vesicle 32 nTPM); blood lineage lineage enriched (granulocytes 6 nTPM); no normal tissue stained high. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas ANGPT1 tissue","url":"https://www.proteinatlas.org/ENSG00000154188-ANGPT1/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000154188 associations","url":"https://platform.opentargets.org/target/ENSG00000154188/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:484","ensembl":"ENSG00000154188","uniprot":"Q15389","entrez":"284","firstDescribed":1994,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Nomura et al, DNA Res, 1994, \"Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/7584026/","biology":"Binds and activates TEK/TIE2 receptor by inducing its dimerisation and tyrosine phosphorylation. Plays an important role in the regulation of angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganisation of the actin cytoskeleton, but also maintenance of vascular quiescence. Required for normal angiogenesis and heart development during embryogenesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signalling cascades. Location: Secreted (UniProt). Locus 8q23.1 (HGNC).","whereFound":[],"targetClass":"other","prevalence":[]},"route":"/targets/angpt1/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}]}}